Twenty-five glaucoma patients and 25 control subjects were recruited for the study. One glaucoma patient was excluded from the final analysis, having reported a history of previous foot cellulitis, which had not been ascertained at the time of recruitment. One control subject was found to have a reproducible visual field defect and other findings consistent with early glaucoma and was therefore excluded from the analysis. Thus the results for 24 glaucoma patients and 24 control subjects are reported.
Demographic data are shown in
Table 1. There were more males in the glaucoma group (
n = 17 [71%] in the glaucoma group versus
n = 9 [38%] in the control group; Mann-Whitney
Z statistic = 2.2,
P = 0.03), and a slightly greater number of glaucoma participants were on either topical or systemic beta blockers compared with controls (glaucoma systemic and/or topical beta blocker use,
n = 8 [33%] versus control systemic beta blocker use,
n = 5 [21%] Mann-Whitney
Z statistic = 0.9,
P = 0.34). However, fewer of the glaucoma group reported a history of one or more falls the previous year (glaucoma fallers,
n = 4 [17%] versus control fallers,
n = 6 [25%] Mann-Whitney
Z statistic = 0.3,
P = 0.74). In the glaucoma group, 19 participants had an overlapping visual field defect, with predominantly upper defects (
n = 8), lower defects (
n = 6), and advanced loss (i.e., only central and temporal visual field remaining;
n = 5). Of the five participants with no overlapping visual field defect, the defects in the worse eye were in either the upper visual field (
n = 2) or lower visual field (
n = 2), with one participant having an advanced visual field defect in one eye only. All control subjects had full visual fields.